Coccidioidomycosis (Valley Fever) is difficult to diagnosis due to lack of awareness and symptoms imitating many other respiratory infections.
Valley Fever is said to cause nearly 30% of all community acquired pneumonia (CAP) cases, but only about 15,000 cases are reported each year in the US.1 IMMY’s simple, rapid LFA allows for better care and stewardship for patients.
| SERUM | Positive % Agreement | Negative % Agreement | PPV | NPV |
|---|---|---|---|---|
| Competitor EIA | 93% | 99% | 94% | 99% |
| Competitor EIA + ID | 92% | 99% | 94% | 99% |
When tested against a competitor’s EIA and ID results, the CTA LFA showed high diagnostic performance in 908 serum specimens.
The CTA LFA agreed with 93% of the competitor’s EIA positive test results, and 99% of their negative test results. When compared to both the competitor’s EIA and ID results, the CTA LFA agreed with 92% of their positive results and 99% of their negative results.
| Coccidioides Antibody LFA | 50 tests | CTA2003 |
|---|